Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 27, 2018

View Archived Issues

siRNA prevents pre-eclampsia in mice and primates

Anti-Andean antibodies protect postexposure

Imiquimod analogue fights more strains of Leishmania

Lung specificity means low tox for inhalable JAK inhibitor

Presepsin is a prognostic marker in congenital heart disease

Phase I results for PIN-201104 support progression to phase II for asthma

First dosing in phase Ib study of EDP-1815 in psoriasis and atopic dermatitis

miR-21 predicts functional worsening in children with CHD-associated pulmonary hypertension

European Commission approves Poteligeo for mycosis fungoides and Sezary syndrome

FDA grants accelerated approval to Vitrakvi for advanced solid tumors with NTRK gene fusion

HBV capsid assembly inhibitors discovered at Shanghai Longwood Biopharmaceuticals

Sanford Burnham Prebys Medical Discovery Institute identifies ACP1 inhibitors

REVOLUTION Medicines synthesizes rapamycin analogues

Cyclin-dependent kinase inhibitors patented by Selection Bioscience

Gene methylation of nontumoral liver tissue predicts recurrence of HCC after surgical resection

BAT-8001, a potent anti-HER2 antibody-drug conjugate, shows promising preclinical profile

Phase I study demonstrates bioequivalence of CT-P16 with the reference bevacizumab products

Aurigene presents AU-15330, a novel dual degrader of SMARCA2/4

G1 Therapeutics reports topline data from second phase II trial of trilaciclib in first-line SCLC

Belgian clearances for phase I trial of anti-IL-7 receptor antagonist OSE-127

Janssen initiates phase I study of live biotherapeutic product VE-202 for IBD

European Commission approves pegfilgrastim biosimilar Ziextenzo

FDA clears IND for phase I trial of AVID-200 in solid tumors

Vivace Therapeutics identifies YAP1/TEAD interaction inhibitors

New BTK inhibitors developed at the Korea Research Institute of Chemical Technology

Cortexyme patents gingipain R1/R2 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...